Form 4: Precision BioSciences CFO's RSU Vesting and Tax Sale

Precision Biosciences CFO John Alexander Kelly reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• John Alexander Kelly, Chief Financial Officer of Precision Biosciences Inc. (DTIL), reported transactions involving the company's common stock.
• On January 20, 2026, a total of 44,363 shares of common stock were acquired through the vesting of Restricted Stock Units (RSUs), comprising 3,888, 13,900, and 26,575 shares from different grant dates.
• On January 21, 2026, Kelly sold 15,213 shares of common stock at a price of $4.03 per share.
• The sale was executed under a Rule 10b5-1 plan, adopted on January 17, 2025, and was solely for the purpose of covering tax withholding obligations associated with the RSU vesting.
• Following these transactions, Kelly's direct beneficial ownership of Precision Biosciences common stock stands at 106,448 shares.

Sentiment

Score: 5

Explanation: The filing details routine executive compensation vesting and a subsequent tax-related stock sale, which is a standard practice and does not indicate any significant positive or negative operational or financial developments for the company.

Positives

• CFO John Alexander Kelly received 44,363 shares of common stock through the vesting of Restricted Stock Units (RSUs), representing a routine component of his executive compensation.

Future Outlook

NA

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025.
• The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Industry Context

NA

Stakeholder Impact

• Shareholders: The transactions are routine and pre-planned, indicating no discretionary selling by the CFO based on new material information, thus having a neutral impact.
• Employees: The report reflects standard executive compensation practices, which is a common aspect of corporate governance.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled transaction by a company executive involving the vesting of Restricted Stock Units (RSUs) and a subsequent 'sell-to-cover' sale to satisfy tax obligations. Such transactions are common and do not reflect a discretionary decision by the insider based on new material information about the company's performance or outlook. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Precision Biosciences, DTIL, Form 4, Insider Transaction, RSU, Restricted Stock Units, Stock Vesting, CFO, John Alexander Kelly, 10b5-1 plan